

Cell Culture Market Size Worth US\$ 44,330.1 million by 2028 says, The Insight Partners

Growing Awareness Regarding Benefits of Cell-Based Vaccines Drives Cell Culture Market

NEW YORK, UNITED STATES, January 10, 2023 /EINPresswire.com/ -- According to The Insight Partners latest study on "Cell Culture Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Product, Application, End User, and Geography," the market was valued at US\$ 21,722.8 million in 2021 and is likely to reach US\$ 44,330.1 million by 2028; it is expected to grow at a CAGR of 10.7% from 2022 to 2028.

Cell-based vaccine is developed from mammalian cell lines instead of embryonic chicken eggs. Cell culture



techniques are alternative options for existing egg-based strategies. Cell culture technology is more flexible than traditional technology relying on an adequate supply of eggs. The main advantage of the cell culture vaccine is its new production process, as it is not dependent on egg supply.

Download sample PDF Copy at: https://www.theinsightpartners.com/sample/TIPRE00003472/

Thermo Fisher Scientific Inc.; Merck KGaA; Danaher Corporation; Corning Incorporated; Eppendorf AG; FUJIFILM Irvine Scientific, Inc.; Lonza Group AG; Sartorius AG; Agilent Technologies, Inc.; and Getinge AB are among the key players profiled during the study of the cell culture market. Several other major companies were studied and analyzed during this research study to get a holistic view of the market and its ecosystem.

Key players involved in the cell culture market are undertaking initiatives to extend their product portfolios and strengthen their market position. For instance, in January 2022, Cytiva (Danaher Corporation) collaborated with Nucleus Biologics to develop custom culture media for cell and gene therapies. Furthermore, market players are making developments in their existing service offerings to improve their market presence. For instance, in February 2022, KromaTiD expanded its service offerings by launching cell and blood culture isolation, processing, and quality control services. Additionally, in November 2019, Thermo Fisher Scientific announced the investment of US\$ 250 million in the US, India, the UK, Argentina, and China. The investment would boost its ability to manufacture cell culture media and expects to complete the work by 2021.

Increasing awareness regarding the benefits of cell-based vaccines and the surging demand for monoclonal antibodies are boosting the cell culture market growth. Furthermore, funding for cell-based research is growing due to the increasing preference for single-use technologies and the rising need for personalized medicine. Moreover, the increasing number of advanced cell culture product launches and FDA approvals for personalized medicines are expected to create opportunities for the market during the forecast period.

Inquiry Before Buying at:

https://www.theinsightpartners.com/inquiry/TIPRE00003472/?utm_source=EINPressWire&utm_medium=10144

The increasing incidence of infectious diseases, such as common cold, diphtheria, E. coli., giardiasis, HIV/AIDS, and the growing risk of COVID 19 outbreak are anticipated to drive vaccine demand worldwide in the coming years. For instance, in India, almost everyone experiences a common cold twice a year, accounting for at least 40–50% of new cases of common cold. Additionally, as per the National Centre for Disease Control (NCDC), in 2019, 28,798 H1N1 cases and 1,218 deaths were reported. Cell culture has become a prominent part of vaccine production in the pharmaceutical industry. Cell culture technology has produced vaccines for rotavirus, polio, smallpox, hepatitis, rubella, and chickenpox.

The cells used to manufacture vaccines are frozen or banked, ensuring an adequate supply of cells for vaccine production. The adoption of cell culture vaccines has grown in recent years due to potential applications in developing viral vaccines, particularly for influenza.

North America dominates the cell culture market. The growth of the market in North America is majorly driven by the increasing technological advancements, growing biotechnology & pharmaceutical industries, surging regulatory approvals for cell culture-based vaccines, and high investments in cell-based research. In November 2019, Thermo Fisher Scientific announced the investment of US\$ 250 million in the US, India, the UK, Argentina, and China. The investment would boost its ability to manufacture cell culture media and expects to complete the work by 2021. Furthermore, the rising incidence of diseases, such as cancer, and strong government funding are fuelling the growth of the overall regional market to a large extent.

Directly Purchase Premium Copy of Cell Culture Market Growth Report at: https://www.theinsightpartners.com/buy/TIPRE00003472/

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

Contact Us:

If you have any queries about this report or if you would like further information, please contact us:

Contact Person: Sameer Joshi

E-mail: sales@theinsightpartners.com

Phone: +1-646-491-9876

Sameer Joshi
The Insight Partners
+ +91 96661 11581
email us here
Visit us on social media:
Facebook

Facebook Twitter LinkedIn

This press release can be viewed online at: https://www.einpresswire.com/article/610525356

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.